Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ, Heptares In Possible $500m+ Oncology Deal

This article was originally published in Scrip

Executive Summary

Japan-headquartered Sosei Group's $400m acquisition of Heptares Therapeutics could prove to be a money spinner as the biotech unit has signed an immuno-oncology focused partnership with pharma major AstraZeneca plc, potentially worth $500m.

You may also be interested in...



Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation

An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.

Juno Picks Up A2a Receptor Via Redox Acquisition

Juno Therapeutics Inc. has followed in the footsteps of some of its big pharma rivals, Novartis and AstraZeneca, by acquiring RedoxTherapies, Inc. for its small molecule adenosine A2a (A2a) receptor antagonist vipadenant.

Heptares-Powered Sosei's Incoming CEO Explains What Happens Next

Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel